A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.

Status:	Completed
Conditions:	Breast Cancer, Lung Cancer, Prostate Cancer, Liver Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Brain Cancer, Thyroid Cancer
Therapuetic Areas:	Oncology
Healthy:	No
Age Range:	18 - Any
Updated:	4/21/2016
Start Date:	July 2007
End Date:	September 2014

An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment

This is a study using sunitinib for patients ending treatment on a previous sunitinib malate
protocol to continue to receive sunitinib. The patient must have been enrolled in one of the
following studies: A6181030, A6181064, A6181078, A6181087, A6181094, A6181107, A6181108,
A6181110, A6181111, A6181112, A6181113, A6181120, A6181126 and A6181170. Other Pfizer
sponsored sunitinib studies may be included in the future.

Inclusion Criteria:

- Must have ended treatment from one of the following sunitinib studies: A6181030,
A6181064, A6181078, A6181087, A6181094, A6181107, A6181108, A6181110, A6181111,
A6181112, A6181113, A6181120, A6181126 and A6181170. Other Pfizer sponsored sunitinib
studies may be included in the future.

Exclusion Criteria:

- See inclusion criteria

We found this trial at

sites

The Strelitz Diabetes Institute of Eastern Virginia Medical School

Norfolk, Virginia 23510

from

Norfolk, VA